Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis

Fig. 3

Maximum purchase price for a course of treatment to remain cost-effective assuming a cost-effectiveness threshold of £20,000 QALY. a Probability of cost-effectiveness for each of the non-dominated programmes over a range of purchasing prices. b Sensitivity analysis on the duration of protection for the monoclonal antibodies and its effect on the maximum purchasing price per course

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us